Introduction
Acute transverse myelitis (ATM) is an acute or subacute spinal cord dysfunction characterised by paraplegia, horizontal level of sensory impairment and sphincter disturbance in which secondary causes such as compressive lesions, tuberculosis, syphilis arteriovenous malformation, trauma and malignant in®ltration have been excluded. 1 The sensory functions can be objectively documented by somatosensory evoked potential (SEP) and motor functions by motor evoked potential (MEP) studies. Median SEPs have been reported to be normal in ATM. However, tibial SEPs are frequently abnormal. 2, 3 Motor evoked potentials are more frequently abnormal and, if unrecordable especially on spinal stimulation, predict a poor prognosis. Corticosteroids are frequently used in the management of ATM. 2, 4, 5 The objective documentation of sensory and motor functions employing evoked potential studies in patients with ATM may be useful. In this communication we report sequential clinical, SEP and MEP ®ndings in patients with ATM following a short course of methyl prednisolone (MPS) therapy.
Patients and methods
Nine patients with ATM within 14 days of the onset of illness have been included in this study. The diagnosis of ATM was based on the criteria of Jeery et al. 6 All the patients underwent a detailed neurological examination. Weakness was graded as per 0-5 Medical Research Council (MRC) scale and tone by Ashworth scale. 7 Tendon re¯ex, pinprick, sense of joint position and vibration were recorded. Blood counts, serum electrolyte, VDRL, collagen pro®le and ELISA for HIV was carried out in all the patients. Cerebrospinal ¯uid was examined for cell, protein, sugar and culture for bacteria and fungi. Spinal MRI was carried out on a 2.0 T superconducting system operating at 1.5 T (Magnetome, SP, Siemens, Germany) using a¯at oval surface coil. All images were obtained employing multislice spin echo sequences (SE) which included gradient motion rephasing to reduce motion induced artefact. T1 (500/15/3, TR in ms/TE in ms/excitation), proton density (2200 ± 2500/15 ± 20/1) and T2 weighted (2200 ± 2500/80 ± 90/1) SE images were obtained in the sagittal plane with slice thickness of 3 mm interslice gap of 0.3 mm and 220/2566256 matrix. The whole spinal cord imaging was completed in two to three examinations.
Median and tibial somatosensory evoked potential Median SEPs were obtained by stimulating the median nerve at the wrist by a 0.1 ms square wave pulse at 3 Hz at an intensity to produce a painless twitch of the thumb. The active surface recording electrode was placed at Erb's point and at contralateral parietal cortex 3 cm behind and 7 cm lateral to vertex using a midfrontal reference. For tibial SEPs, the posterior tibial nerve was stimulated below the medial malleolus at 3 Hz sucient to produce a painless twitch of the big toe. The recording electrode was placed on the spinous process of the ®rst lumbar vertebra (L 1 ) and 2 cm caudal to Cz (Cz'). The reference electrodes were placed at L 3 and Fz respectively. The impedence of the electrode was kept below 5 KO, the frequency bandpass was 2 ± 3000 Hz and analysis time 100 ms. Five hundred and twelve responses were twice averaged at a gain of 1 ± 2 mV/division to ensure reproducibility employing Neuromatic 2000 (Dantec, Denmark). Median SEPs were analyzed by the latency of N 9 , N 20 and interpeak latency of N 9 ± N 20 . For tibial SEPs latencies N 21 , P 40 and N 21 ± P 40 conduction time (Central sensory conduction time) were measured. 3 Motor evoked potential (MEP) Motor evoked potentials were recorded from both upper and lower limbs bilaterally following transcranial electrical stimulation of the cortex and spine. A Digitimer D-180 (England) stimulator delivering an electrical shock up to 750 V with a time constant of 50 ± 100 ms was used. The stimulating electrode was a 1 cm diameter saline soaked with felt pads mounted on a plastic handle. To activate abductor digiti minimi (ADM), the cathode was placed at the vertex and anode 7 cm laterally and 1 cm anterior to a line drawn from the vertex to tragus. For activating tibialis anterior (TA) the anode was kept at the vertex and cathode 7 cm posterior. For cervical and lumbar stimulation the cathode was placed below the spinous process of the seventh cervical (C 7 ) and twelfth thoracic vertebra (T 12 ) respectively and the anode proximal. Motor evoked potentials were recorded by surface electrodes, placed on ADM or TA in a belly tendon montage. During the cortical stimulation, the patient was asked to contract the target muscle slightly (10% of the maximum force irrespective of degree of weakness). During spinal stimulation, the patient was asked to relax. Electromyogram signals were ®ltered through 20 Hz ± 2 KHz at a gain of 0.5 ± 1 mV/division. The stimulus intensity was 90 ± 100% for cortical and 50 ± 60% of the maximum output for spinal stimulation. Three responses were obtained at 10 s intervals and the one with the shortest latency was recorded. Onset latency and the amplitude of the negative phase was measured. Central motor conduction time to abductor digiti minimi (CMCT-ADM) was calculated by subtracting the latency on cervical (C 7 ) stimulation from that on cortical stimulation and that for the Tibialis anterior (CMCT-TA) by subtracting the latency on lumbar (L 1 ) stimulation from that on vertex stimulation. 3 The reports of evoked potentials were compared with the normal values of our laboratory which were obtained from 32 healthy adult volunteers. Their age ranged between 15 and 60 years. The upper limit of normal was de®ned by mean+2.5 SD of controls. The upper limit of CMCT-ADM (mean+SD) was 8.1 (5.1+1.2)ms, CMCT-TA 16.1 (12.1+1.6)ms, median N9-N20 conduction time 11.3(8.3+1.2)ms and tibial N21-P40 conduction time was 27.1 (20.1+2.8)ms.
In the follow-up studies, the improvement in evoked potentials was de®ned if the change exceeded the normal intra-individual variation. To determine the normal intra-individual variation, normal volunteers were subjected to MEP and SEP studies for three consecutive days and the maximum dierence was analysed. The mean (SE) of maximum dierence for CMCT-TA was 0.79 (0.15) ms and that for tibial central sensory conduction time (CSCT) was 0.53 (0.14) ms. The upper limit of normal intra-individual variability was de®ned as mean +2.576 SE which covers 99% of normal variability. 8 The relationship between evoked potential with clinical variables was evaluated by chi square (w2) test. The extent of MRI changes (®ve spinal segments or more) were correlated with 3 month outcome employing w2 test.
Treatment and follow-up
All the patients received methylprednisolone 500 mg intravenously injected over 6 h for ®ve consecutive days. The clinical and evoked potential studies were carried out before MPS therapy and repeated on 7 and 90 days after the treatment.
Outcome
The outcome was de®ned on the basis of a 3 month Barthel Index score. A score below 12 indicated poor and 12 or more as good recovery.
Results
Nine patients with ATM received MPS therapy of whom three were females. Their age ranged between 12 and 42 (mean 25.5) years. History of fever was present in ®ve patients and pain and paresthesiae in seven. The weaknesses peaked by 1-14 (mean 3 3 , protein 120 (range 20-300)mg/dl and sugar 50 (range 40 ± 60) mg/dl. Cerebrospinal¯uid was negative for bacterial and fungal cultures, HIV and VDRL in all the patients. Collagen pro®le was also negative in all the patients. Spinal MRI was carried out in eight patients. On T2 sequence there were hyperintense signal changes extending from 2 ± 18 spinal segments. The signal changes were present in the cervical region in ®ve, dorsal in ®ve and lumber in one patient.
Evoked potential changes
Motor evoked potentials were more frequently abnormal compared to SEP. The MEP was abnormal in eight patients whereas SEP in six. The upper limb central motor conduction time was abnormal in two patients; prolonged bilaterally in one and unilaterally in the other. Lower limb CMCT was abnormal in eight patients, unrecordable in ®ve patients (nine sides) and prolonged in three patients (six sides). Median SEPs were normal in all and tibial were abnormal in six patients; unrecordable in ®ve (eight sides) and prolonged in one patient (one side).
Eect of methyl prednisolone therapy
Following MPS therapy, there was I MRC grade improvement of lower limb power in six patients (12 sides), which correlated with improvement in CMCT-TA in four patients (six sides). Both the patients with upper limb CMCT abnormalities improved following MPS treatment with respect to muscle power and CMCT-ADM values. In two patients, clinical improvement was not associated with MEP improvement. On the other hand, in 1 patient whose MEP improved, there was no clinical recovery. At 3 months, further improvement was noted in muscle power in eight patients which ranged between grade 1 and 5. It correlated with CMCT improvement in ®ve patients (nine sides).
Following MPS therapy joint position sensation improved in two patients. Tibial SEP, however, improved in four patients (4 sides) becoming recordable in one and in the remaining there was improvement in CSCT. At the 3 months follow-up, tibial CSCT improved further in six patients (ten sides). CMCT and CSCT although improved on seventh day after MPS therapy, however, the improvement was more marked at the 3 month follow-up. The sequential changes in lower limb good (20) poor (4) good (20) good (20) poor (4) good (19) poor (4) good (20) good (20) NR=not recordable, BI=Barthel index score at 3 months, ND=not done, R=right, L=left
Evoked potential changes in transverse myelitis J Kalita et al muscle power, CMCT-TA, joint position sensations and tibial CSCT are shown in Tables 1 and 2 . At the 3 months follow-up six patients had good and three poor recovery. In two patients, the MRI changes were restricted to ®ve spinal segments or less and both recovered well by 3 months. Five out of six patients with extensive signal alternation on spinal MRI exceeding ®ve segments also recovered well. The extent of MRI signal changes did not correlate with outcome (w 2 =0.38, df-1, NS). MEP correlated with the degree of weakness (w 2 =9.0, df=2, P50.01) and the outcome (w 2 =9.0, df=2, P50.01); whereas SEP neither correlated with sensory loss (w 2 =2, df=2, NS) nor with outcome (w 2 =1.3, df=2, NS).
Discussion
In our study, the lower limb MEP and SEP were more frequently abnormal compared to the upper limb. This could be due to more severe involvement of the thoracid region of the spinal cord in ATM. The involvement of the cervical region of the spinal cord in ATM has been reported to be common if MRI and evoked potential changes are also included. 3 Of the two evoked potentials, MEPs were more frequently abnormal (eight out of nine patients) compared to the SEP (six out of nine patients). Two main abnormalities in evoked potentials were noted; inexcitable sensory or motor pathways and prolonged central conduction time. Prolongation of conduction time may be due to demyelination, damage to fast conducting pathways and desynchronisation of descending volleys. 9 Unrecordable evoked potentials may be due to damage in fast conducting pathways. In ATM, a varying degree of white and gray matter changes in the spinal cord have been reported. 10 Presence of white matter changes may lead to prolongation of CMCT or CSCT whereas combined white and gray matter involvement may lead to unrecordable SEP, MEP or both. 3 On the seventh day of intravenous MPS therapy, six patients improved clinically. Motor evoked potential improvement, however, was noted in four of these patients. In two patients, clinical improvement was not associated with MEP improvement. On the other hand, in one patient, MEP improved but there was no clinical recovery. In CMCT studies, the fastest conducting ®bres are evaluated which are responsible for phasic movements; whereas muscle power testing relies on tonic muscle contraction which is a function of slow conducting motor pathways. 10, 11 This can 
good (20) poor (4) good (20) good (20) poor (4) good (19) poor (4) good (20) good (20) NR=not recordable, ab=abnormal, N=normal, BI=Barthel index score at 3 months, ND=not done, R=right, L=left Figure 1 Eect of methyl prednisolone therapy in acute transverse myelitis (patient no. 4). Unrecordable CMCT-TA became recordable at a 3 month follow-up but was prolonged in the left side. The patient recovered completely at 3 months
Evoked potential changes in transverse myelitis J Kalita et al account for the occasional discrepancy between muscle power and CMCT. Clinical sensory testing was unchanged at 1 week; however, CSCT improved in four patients. The early improvement after MPS therapy may be due to antioedema eect and clearing of conduction block. At the 3 months follow-up, further improvement was noted in both MEP and SEP. The MEP improvement was associated with clinical improvement in ®ve patients. The improvement at 3 months was more pronounced compared to that at 7 days after MPS therapy. The improvement at this stage may be multifactorial and may depend on remyelination, collateral sprouting and neuronal plasticity. The role of MPS in multiple sclerosis is well documented and its bene®cial role in ATM has also been reported. 4, 5, 12, 13 More pronounced clinical improvement at 3 months compared to 7 days after MPS therapy may be due to a natural process of improvement although a delayed bene®cial eect of MPS cannot be ruled out. The answer to this question requires a double blind controlled trial. The natural history of ATM is variable ranging between complete recovery to disabling neurological de®cit; About one third of patients with ATM have been reported to have a good recovery, one third fair and one third poor or no recovery. 14 In the present study, only three patients had a poor recovery. In an earlier study on ATM in which corticosteroids were not used, seven out of ten patients had a poor outcome suggesting a possible role of MPS in ATM. In the earlier study, CMCT-TA improved in two patients and CSCT only in one side at a 3 month follow-up. 3 The present study suggests a possible bene®cial eect of Methyl prednisolone in ATM. A larger controlled study, however, is needed to evaluate further the role of MPS in ATM.
